1. Home
  2. AMTX vs ENGN Comparison

AMTX vs ENGN Comparison

Compare AMTX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aemetis Inc. (DE)

AMTX

Aemetis Inc. (DE)

HOLD

Current Price

$1.14

Market Cap

134.2M

Sector

Industrials

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

N/A

Current Price

$1.57

Market Cap

117.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AMTX
ENGN
Founded
2005
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
134.2M
117.2M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
AMTX
ENGN
Price
$1.14
$1.57
Analyst Decision
Buy
Buy
Analyst Count
4
9
Target Price
★ $13.38
$3.29
AVG Volume (30 Days)
694.5K
★ 809.7K
Earning Date
11-05-2026
12-21-2026
Dividend Yield
N/A
N/A
EPS Growth
32.98
★ 56.85
EPS
★ N/A
N/A
Revenue
★ $77,194,000.00
N/A
Revenue This Year
$24.86
N/A
Revenue Next Year
$44.09
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 174.60
N/A
52 Week Low
$1.14
$1.40
52 Week High
$3.80
$12.25

Technical Indicators

Market Signals
Indicator
AMTX
ENGN
Relative Strength Index (RSI) 27.43 35.71
Support Level N/A $1.40
Resistance Level $1.87 $1.95
Average True Range (ATR) 0.10 0.09
MACD -0.01 -0.01
Stochastic Oscillator 3.66 10.04

Price Performance

Historical Comparison
AMTX
ENGN

About AMTX Aemetis Inc. (DE)

Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. The operations include California Ethanol, California Dairy Renewable Natural Gas and India Biodiesel. It operates in the reportable geographic segments of North America and India.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: